EP0356192A2 - Verhütung und Behandlung von Lebergeschwüren bei Tieren - Google Patents

Verhütung und Behandlung von Lebergeschwüren bei Tieren Download PDF

Info

Publication number
EP0356192A2
EP0356192A2 EP89308477A EP89308477A EP0356192A2 EP 0356192 A2 EP0356192 A2 EP 0356192A2 EP 89308477 A EP89308477 A EP 89308477A EP 89308477 A EP89308477 A EP 89308477A EP 0356192 A2 EP0356192 A2 EP 0356192A2
Authority
EP
European Patent Office
Prior art keywords
antibiotics
virginiamycin
family
component
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89308477A
Other languages
English (en)
French (fr)
Other versions
EP0356192A3 (de
Inventor
Richard Dwane Hedde
Roseanna H. N. Quach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0356192A2 publication Critical patent/EP0356192A2/de
Publication of EP0356192A3 publication Critical patent/EP0356192A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to the use of an antibiotic which is a member of the Virginiamycin family of antibiotics in the manufacture of a medicament for preventing and treating liver abscess in animals.
  • This invention further relates to pharmaceutical compositions for use in the prevention and treatment of liver abscesses in animals by combining a first component which is a member of the Virginiamycin family of antibiotics with a second component which is a member of the ionophore family of antibiotics.
  • the Virginiamycin family of antibiotics have generally been employed in the treatment of bacterial infections wherein the causative organism is a gram-positive bacteria and as a growth promotant in swine, poultry and beef cattle.
  • the art does not disclose or suggest that the Virginiamycin family of antibiotics would be useful in treating liver abscesses in animals wherein the gram-negative bacteria Fusobacterium necrophorum appears to be the predominant causative organism.
  • the ionophore family of antibiotics have generally been employed as a growth promotant in feedlot cattle. Olentin, Feed management 33, pp. 14-24:, Brown et al. , Journal of Animal Science , 37, pp. 1085-­1091 (1973). However, the ionophore family of antibiotics have not provided a satisfactory means for controlling liver abscesses in cattle or sheep.
  • Fusobacterium necrophorum also referred to as Fusiformis necrophorus , Bacillus necrophorus or Sphaerophorus necrophorus .
  • Fusobacterium necrophorum has been divided into three biotypes, namely A, B and C, of which only biotyloes A and B have been implicated in the formation of liver abscesses (Scanlan et al. , Cornell Vet. 1983, 73, 288-297). This organism is widespread in nature and apparently proliferates rapidly at the sites of wounds in animals or on the skin or mucous membrane of animals.
  • the microorganism can enter the bloodstream through cuts and lesions in the hoof-area of animals.
  • the organism may be found in the digestive tract of healthy animals, in manure and in soil.
  • the bacteria can also enter the bloodstream through a lesion that may form in the rumen as a result of the ingestion of a high concentrate diet.
  • the bacteria which enters the bloodstream will be filtered out by the liver and thus eventually colonize and grow in the liver.
  • the animal which has been most affected by abscessed livers are beef cattle and dairy cattle. Hale, "Liver Abscesses and Founder," Animal Health Nutrition, September (1985).
  • liver abscesses were originally not considered to be a major problem in animals until a high concentrate diet became a common method of feeding such animals.
  • Antibiotics and chemotherapeutic agents that have been utilized with some success in the treatment of liver abscesses include: Tetracycline antibiotics, Sulphanomides, Pyrazinines, Monensin and Tylosin. Poter et al. , Journal of Animal Science , 61, pp. 1058-1065 (1985); Brown et al. , Journal of Animal Science , 37, pp. 1085-1091 (1973); and Adam, U.S. Patent No. 4,061,751 (December 6, 1977). Such treatments have not, however, provided entirely satisfactory control of liver abscesses in animals.
  • antibiotics from the Virginiamycin family of antibiotics either alone or in combination with a member of the ionophore family of antibiotics are effective in the treatment and prevention of liver abscesses in beef and dairy cattle, wherein the gram -negative bacterium, Fusobacterium necrophorum appears to be the predominant causative organism.
  • This invention relates to the use of an antibiotic in the manufacture of a medicament from the Virginiamycin family of antibiotics for treating and preventing liver abscesses in animals.
  • a representative antibiotic from the Virginiamycin family of antibiotics is Virginiamycin factor M.
  • This invention further relates to the use of an antibiotic from the Virginiamycin family of antibiotics in the manufacture of a medicament for treating and preventing liver abscesses in beef cattle and dairy cattle, wherein the gram-negative bacteria Fusobacterium necrophorum appears to be the predominant causative organism.
  • This invention also relates to pharmaceutical compositions for use in treating and preventing liver abscesses in animals by combining a first component which is a member of the Virginiamycin family of antibiotics with a second component which is a member of the ionophore family of antibiotics wherein the gram-negative bacteria Fusobacterium necrophorum appears to be the predominant causative organism.
  • a first component which is a member of the Virginiamycin family of antibiotics with a second component which is a member of the ionophore family of antibiotics will provide a synergistic effect in the treatment of liver abscesses in animals in need thereof.
  • an effective amount of an antibiotic from the Virginiamycin family of antibiotics is administered to the animal.
  • a first component which is a member of the Virginamycin family of antibiotics with a second component which is a member of the ionophore family of antibiotics will provide a synergistic effect in the treatment and prevention of liver abscesses in animals wherein Fusobacterium necrophorum appears to be the predominant causative agent.
  • an "effective amount” as used herein will be that amount which when delivered in vivo to animals causes an observable improvement to a liver abscess in such animals or prevents the formation of a liver abscess in such animals.
  • Each of the antibiotics from the Virginiamycin family of antibiotics which can be employed in this invention are known in the prior art. Many are commer­cially available and are employed in the treatment of gram-positive bacterial infections in animals as well as in the stimulation of growth in domestic animals such as poultry, swine, sheep and cattle.
  • Each antibiotic from the Virginiamycin family of antibiotics may be assigned to either one of the two basic primary structures, A and B. Although the two structures are structurally different, they each contain a macrocyclic lactone peptolide chemical structure.
  • the A primary structures are polyunsaturated cyclic peptolides which can be considered as highly modified depsipeptides having a molecular weight of about 500. The members of this group were established by X-ray crystallography and mass spectrometry and by identification of the hydrolysis products.
  • the B structures are generally characterized as cyclic hexadepsipeptides having a molecular weight of about 800. The B structures were largely established by chemical identification of the hydrolysis products.
  • Table 1 is representative of various A and B groups from the Virginiamycin family of antibiotics which may be used in this invention.
  • Table I Antibiotics from the Virginiamycin Family of Antibiotics Complex antibiotic Type A components
  • Type B components Madumycin (A2315A) Madumycin II Madumycin I Mikamycin Mikamycin A Mikamycin B Ostreogrycin (E129) Ostreogrycins A,C,D,G,Q Ostreogrycins B (B1,B2,B3) Patricin Patricins A and B Plauracin Plauracin II Plauracin I Pristinamycin (Pyostacin) Pristinamycins II (A and B) Pristinamycins I (A, B and C) Streptogramin Streptogramin A Streptogramin B Synergistins (PA114) Synergistin A Synergistins B (1 and 3) Vernamycin Vernamycin A Vernamycins B (a, , , ) Griseovi
  • the antibiotics from the Virginiamycin family of antibiotics may contain more than one factor.
  • Virginiamycin may contain components referred to as Virginiamycin M1 and M2 (collectively known as Factor M) as well as Virginiamycins S1, S2, S3 and S4 (Collectively known as Factor S).
  • the Virginiamycin-type antibiotic known as "A-2315" may contain factors A, B and C (see U.S. Patents 3,923,980 and U.S. 4,336,250). Accordingly, the various factors of each of the antibiotics from the Virginiamycin family of antibiotics are contemplated for use in this invention.
  • any reference to an antibiotic contained herein will include within such term all the various factors which can be employed individually or in combination with one another, or as a complex of all such factors.
  • the preferred antibiotics from the Virginiamycin family of antibiotics include Madumycin, Mikamycin, Ostreogrycin, Patricin, Plauracin, Pristinamycin, Streptogramin, Synergistins, Vernamycin or Virginiamycin, or factors thereof.
  • Each of the antibiotics from the ionophore family of antibiotics which can be employed in this invention are known in the prior art. A number of these compounds are in commercial use and were originally used as anticoccidial feed additives for poultry.
  • Each of the antibiotics from the ionophore family of antibiotics is characterized by containing a multiplicity of cyclic ethers in their structures and is generally referred to as a carboxylic polyether ionophore.
  • the antibiotics from the ionophore family of antibiotics are produced by the streptomyces genus of microorganisms. Bergen et al. , Journal of Animal Science, 58, pp. 1465-1539; and Kirk-Othmer: Encyclopedia of Chemical Technology, Vol. 3, Third Edition (John Wiley & Sons, Ind., 1978) at page 47.
  • the antibiotics from the ionophore family of antibiotics may contain more than one factor. Each of the factors may be used in the present invention. It is further anticipated that antibiotics from the ionophore family of antibiotics can form ethers, salts, esters, or other derivatives which are contemplated for use in this invention.
  • the antibiotics from the ionophore family of antibiotics which can be employed in this invention include Monensin, Ionomycin, Inidlomycin, Nigenicin, Grisorixin, Dianemycin, Lenoremycin, Salinomycin, Narasin, Ionomycin, Arborixin, Septamycin, Etheromycin, Lasalocid (factors A, B, C, D and E), Mutalomycin, Isolasalocid A, and Laidomycin and Lysocellin and factors thereof.
  • a complete list of antibiotics from the ionophore family of antibiotics which can be used in this invention is extensively reviewed and set forth in U.S. Patent 4,405,609. This reference is incorporated herein by reference, and is illustrative of the members of the ionophore family of antibiotics which can be employed in this invention.
  • Preferred antibiotics from the ionophore family of antibiotics include Monensin, Narasin, Lasalocid, Lysocellin, Salinomycin, Ionomycin, Nigenicin and Dianemycin.
  • the preferred antibiotic, Monensin a compound widely used as a growth promotant in animals (see U.S. Patent No. 3,839,557) includes the various active factors A, B, and C, the alkali metal salts thereof such as sodium and the like and the esters thereof such as carbamate esters and the like.
  • Another preferred antibiotic, Narasin is produced by submerged aerobic fermentation of Streptomyces aureofaciens and includes the active factors A, B and D, esters and physiologically acceptable salts thereof.
  • a typically preferred ester of Narasin includes lower alkyl esters having 1 to 4 carbon atoms such as methyl esters.
  • An antibiotic from the Virginiamycin family of antibiotics can be administered to animals by any of several alternative methods. They can be orally administered to the animals by forming a homogeneous admixture of an antibiotic from the Virginiamycin family of antibiotics with a commercial dry feed or ration or by initially forming a concentrated premix by mixing the active antibiotic from the Virginiamycin family of antibiotics with a suitable, non-toxic, edible carrier material.
  • suitable carriers include corn meal, germ meal or other cereals, soy flour, soya grits, seed meal, oyster shell flour, calcium silicate, and the like, and may additionally contain other compatible medicaments.
  • the antibiotic from the Virginiamycin family of antibiotics will be administered as a feed additive in the range of about 1 to about 100 grams of active ingredient per ton of feed, preferably from about 5 to about 50 grams of active ingredient per ton of the animal feed.
  • This invention also provides a composition containing a first component from the Virginiamycin family of antibiotics in combination with a second component from the ionophore family of antibiotics.
  • the components of the present invention are employed in amounts which in combination produce an unexpected synergistic effect.
  • the combination of the first component from the Virginiamycin family of antibiotics with the second component from the ionophore family of antibiotics can be administered to animals by any of several alternative methods.
  • the compositions of this invention can be orally administered to the animals by forming a homogeneous admixture of the first component from the Virginiamycin family of antibiotics with the second component from the ionophore family of antibiotics with a commercial dry feed or ration.
  • the compositions of this invention can further be orally administered to the animal by initially forming a concentrated premix containing the first and second components of this invention with a suitable, non-toxic, edible carrier material.
  • suitable carriers include cornmeal, germ meal or other cereals, soy flour, soya grits, seed meal, oyster shell flour, calcium silicate, and the like, and may contain other compatible medicaments.
  • the respective components from the Virginiamycin family of antibiotics and the ionophore family of antibiotics will be present on a weight basis in a ratio of about 1 to about 10 parts of the first component from the Virginiamycin family of antibiotics together with about 1 to about 10 parts of the second component from the ionophore family of antibiotics.
  • the antibiotics from the first and second components will each be administered as a feed additive in the range of about 1 to about 100 grams of active ingredient per ton of feed. Preferably from about 5 to about 50 grams of active ingredient.
  • a typical feedstuff for feed lot animals has the following composition. Ingredient Percent Coarse ground corn 69.95 Ground corncobs 10.00 Soybean meal (50% protein) 8.00 Alfalfa meal 5.00 Molasses 5.00 Urea 0.60 Dicalcium phosphate 0.50 Calcium carbonate 0.50 Salt 0.30 Vitamin A and D2 premix 0.07 Vitamin E premix 0.05 Trace mineral premix 0.03 100.00
  • premixes in accordance with this invention can advantageously contain from about 0.125% by weight to about 40% by weight of an antibiotic from the Virginiamycin family of antibiotics, preferably from about 0.5 to about 25% by weight, and most preferably about 5% by weight of an antibiotic from the Virginiamycin family of antibiotics.
  • premixes may be readily mixed with the feed or ration by conventional techniques in the art.
  • premixes in accordance with this invention can advantageously contain from about 0.125% by weight to about 40% by weight of an antibiotic from the Virginiamycin family of antibiotics, preferably from about 0.5% to about 25% by weight, and most preferably about 1 to about 5% by weight of the Virginiamycin family of antibiotics, in combination with a second component from the ionophore family of antibiotics in an amount of from about 0.25 by weight to about 40% by weight, preferably from about 0.5 to about 25% by weight, and most preferably from about 2 to about 10% by weight of the ionophore family of antibiotics.
  • Such premixes may be readily mixed with the feed or ration by conventional techniques in the art.
  • parenteral therapy may be utilized in this invention as a means of administering the antibiotic from the Virginiamycin family of antibiotics to the animals.
  • a single dosage of from about 10 to about 100 mg., preferably from about 25 to about 50 mg. of the antibiotic from the Virginiamycin family of antibiotics per kilogram of body weight of the animal to be treated is utilized.
  • the dosage regimen for such parenteral therapy may vary according to the age and type of animal, severity of the liver abscesses, and the like. For most therapeutic situations, a single daily dosage is required to be maintained for a period of 4 days. However, parenteral therapy for up to 10 days may be required in the instance of a severe liver abscess. The extent of parenteral dosage may be determined within the discretion of the attending veterinarian.
  • an antibiotic from the Virginiamycin family of antibiotics or the combination of the first component from the Virginiamycin family of antibiotics with the second component from the ionophore family of antibiotics can be administered to the animals in the form of a controlled release formulation such as polymers, waxes and the like.
  • a controlled release formulation such as polymers, waxes and the like.
  • slow release excipients include a slow release ruminant pellet, bolus, capsule, implant, or similar prolonged payout device which is capable of effective oral delivery of the first and second components to the animal over a prolonged period of time of up to 3 months or longer.
  • Controlled release formulations containing a composition of this invention and a carrier can be prepared by methods known in the art. See, for example, U.S. Patent Nos. 4,333,919; 4,331,652; and 4,293,539.
  • the controlled release formulations can be prepared by mixing an antibiotic from the Virginiamycin family of antibiotics or the combination consisting of a first component from the Virginiamycin family of antibiotics with a second component from the ionophore family of antibiotics with a copolymer derived from the condensation of about 60 to about 95 parts by weight of lactic acid and about 5 to about 40 parts by weight glycolic acid.
  • the mixture so formed can be molded into a tablet, or placed inside of a bolus for oral administration to the animal.
  • the formulated composition is slowly degraded so that the animal will receive an effective amount of the first and second component over an extended period of time. This method is particularly effective in ruminant containing animals.
  • a parenteral therapy may be utilized in this invention as a means of administering the combination of the first component from the Virginiamycin family of antibiotics with the second component from the ionophore family of antibiotics to the animals.
  • an effective but non-toxic quantity of the antibiotic from the Virginiamycin family of antibiotics or the combination of an antibiotic from the Virginiamycin family of antibiotics with an antibiotic from the ionophore family of antibiotics are administered to monogastric or ruminant, meat-or milk-producing animals for use in treating liver abscesses.
  • the animals which can be treated by this invention include beef cattle, dairy cattle, sheep, swine, poultry, horses and rabbits.
  • the preferred animals which can be treated by this invention include beef cattle and dairy cattle.
  • a cattle ration was prepared using the following formula: Proportion (%) As Is Air Dry Corn 69.0 82.0 Alfalfa hay 2.5 3.0 Corn Silage 24.5 10.0 Supplement 4.0 5.0
  • the ration was supplemented with varying proportions of Virginiamycin and fed, ad libitum, to approximately 200 cattle weighing between 650 lbs. and 850 lbs.
  • the cattle were processed according to standard procedures for the facility, individually weighed and identified. The treatments were continued until the cattle reached an approximate weight of 1100 lbs. (approximately 120 days).
  • livers were identified with the individual animal number and scored for liver abscess after examination in the manner required by USDA. Livers were palpated and suspicious area were excised and examined for the presence of liver abscesses.
  • liver abscess The incidence of liver abscess is summarized below: Table 3 Liver Abscess Vm (grams/ton) O 9.1 22.7 45.5 No. of Animals With Liver Abscess 26 16 12 6 No. of Animals Without Liver Abscess 173 181 185 191 Total Animals 199 197 197 197 197
  • microbiological studies were initiated with Virginiamycin and other antibiotics so as to determine their potency in controlling liver abscesses.
  • Fusobacterium necrophorum has been associated with bovine liver abscesses in cattle, it was determined that microbiological studies involving this bacterium would be undertaken with representative examples of antibiotics including Virginiamycin.
  • the MIC's for Fusobacterium necrophorum was done by the agar dilution method. Two-fold serial dilutions of each compound was incorporated into Wilkins-Chalgren Agar plates. Each Fusobacterium necrophorum was propagated in Peptone-Yeast-Glucose broth and inoculated onto the plates with a multipoint inoculating device. The plates were incubated at 37°C in an atmosphere of 10% H2, 5% CO2 and 85% N2, for 40 hours.
  • Table I indicates that Virginiamycin was twice as effective as Tylosin against the strain of Fusobacterium necrophorum ATCC 27852, and was comparable to Tylosin against the other two strains. Both were less effective (higher MICs) than Chlortetracycline, Oxytetracycline and Flavomycin. Virginiamycin was further superior (lower MICs) than Erythromycin, the ionophores, zinc Bacitracin and the glycopeptides AAD216 and Avoparcin. In the one experiment in which factors M and S of virginiamycin were tested, the MICs were 0.35 (geometric mean for the two ATCC strains) and greater than 32 ⁇ g/ml, respectively. Virginiamycin contains 75% of Factor M and 25% of Factor S.
  • microbiological studies were initiated with combinations of antibiotics from the Virginiamycin family of antibiotics and ionophore family of antibiotics so as to determine their potency in controlling liver abscesses.
  • Fusobacterium necrophorum has been associated with bovine liver abscess in cattle, it was determined that microbiological studies involving this bacterium would be undertaken. Since the liver abscess etiology is poorly defined, it is difficult to precisely extrapolate these studies to animal disease.
  • the responses set forth in the table below clearly suggest that combinations of antibiotics from the virginiamycin family of antibiotics and the ionophore family of antibiotics would be useful in controlling the primary pathogen associated with liver abscesses.
  • Virginiamycin was combined with an antibiotic from the ionophore family in a ratio expected in medicated feeds, eg. Salinomycin at 20 g/Ton and Virginamycin at 15 g/Ton have a ratio of 1.3:1.
  • a stock solution was made up to contain Salinomycin and Virginiamycin in the same ratio of 1.3:1.
  • the stock solution was serially diluted two fold. The dilutions were incubated with F. necr .
  • the end point was the lowest concentrations antibiotics which inhibited the growth of F. necr ., or MIC for minimal inhibitory concentration, eg. the MIC of Salinomycin was 5 ⁇ g/ml while that of Virginiamycin was 1 ⁇ g/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19890308477 1988-08-24 1989-08-22 Verhütung und Behandlung von Lebergeschwüren bei Tieren Withdrawn EP0356192A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23584488A 1988-08-24 1988-08-24
US23606788A 1988-08-24 1988-08-24
US235844 1988-08-24
US236067 1994-05-02

Publications (2)

Publication Number Publication Date
EP0356192A2 true EP0356192A2 (de) 1990-02-28
EP0356192A3 EP0356192A3 (de) 1990-12-27

Family

ID=26929271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890308477 Withdrawn EP0356192A3 (de) 1988-08-24 1989-08-22 Verhütung und Behandlung von Lebergeschwüren bei Tieren

Country Status (2)

Country Link
EP (1) EP0356192A3 (de)
JP (1) JPH0291026A (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652716B2 (en) * 1990-02-13 1994-09-08 Astellas Pharma Inc. Method for treating hepatic diseases using FK 506 and related compounds
WO1999007361A1 (en) * 1997-08-05 1999-02-18 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483779D1 (de) * 1983-12-23 1991-01-31 American Cyanamid Co Antimikrobielle tierfutterzusatzzusammensetzungen.
PT90176B (pt) * 1988-03-30 1994-06-30 Rowe James Baber Processo para a preparacao de um agente de tratamento de gado equideo

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652716B2 (en) * 1990-02-13 1994-09-08 Astellas Pharma Inc. Method for treating hepatic diseases using FK 506 and related compounds
WO1999007361A1 (en) * 1997-08-05 1999-02-18 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
US6271256B1 (en) 1997-08-05 2001-08-07 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals with bicyclo spiroether compounds

Also Published As

Publication number Publication date
JPH0291026A (ja) 1990-03-30
EP0356192A3 (de) 1990-12-27

Similar Documents

Publication Publication Date Title
US4394377A (en) Ruminant animal performance by co-administering choline and propionate enchancers
JP6415430B2 (ja) 反芻動物の乳房炎の予防または治療剤
HU203667B (en) Process for producing synergetic zootechnical compositions containing three components
RU2145845C1 (ru) Капсула пролонгированного выделения и способ увеличения прироста массы и/или предотвращения болезненного состояния у жвачных животных, способ увеличения поглощения селена у жвачных животных
US4336250A (en) Lactation improvement method
US4405609A (en) Combination and method for increasing feed utilization efficiency in ruminants
EP0356192A2 (de) Verhütung und Behandlung von Lebergeschwüren bei Tieren
HU182652B (en) Process for producing food-additives containing antibiotics
EP0057072B1 (de) Verbindung und Verfahren zur Verbesserung der Futterverwertung bei Wiederkäuern
US4260631A (en) Oral administration of Salinomycin to pigs
WO1999032144A1 (en) Method for preventing/remedying mastitis
EP0063491B2 (de) Verfahren zur Verbesserung der Milcherzeugung
EP0517394B1 (de) Vorbeugende/therapeutische Zusammensetzung für die Pleuropneumonie des Schweins
US4237116A (en) Combination of thiopeptin and rumensin to improve ruminant feed efficiency
US3790669A (en) Synergistic tylosin and furazolidone medication for calf pneumoenteritis complex
EP0597167A1 (de) Antibiotische Mischung von Gentamicin mit Lincomycin enthaltendes, veterinäres Präparat als Zusatzmittel für Trinkwasser oder Tierfutter und dessen Verwendung in der Aufzucht von Schweinen
KR950009945B1 (ko) 음료수 또는 동물사료에 첨가제로서 겐타마이신과 린코마이신의 항생제 혼합물을 함유하는 수의제제 및 이의 돼지사육에 대한 용도
EP3838347B1 (de) Evernimicin zur behandlung von erkrankungen wie nekrotischer enteritis
CA1059910A (en) Control of lactic acidosis in ruminants
US4292318A (en) Product and method for combating swine dysentery
US3719758A (en) Method of promoting growth and improving feed efficiency in poultry and swine via oral administration of cephalosporin c
US4123522A (en) Control of bloat in ruminants
KR20260000188A (ko) 락토바실러스 파라카세이를 포함하는 사료 첨가제 조성물
KR20150094885A (ko) 반추동물의 생산성을 증진시키기 위한 미생물 및 이의 이용
HU201668B (en) Method for producing veterinary preparation and fodder premixture of synergetic effect serving for making more economical breeding of animals

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890830

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19910621